Antibiotic-Mediated Modulations of Outer Membrane Vesicles in Enterohemorrhagic Escherichia coli O104:H4 and O157:H7

ABSTRACT Ciprofloxacin, meropenem, fosfomycin, and polymyxin B strongly increase production of outer membrane vesicles (OMVs) in Escherichia coli O104:H4 and O157:H7. Ciprofloxacin also upregulates OMV-associated Shiga toxin 2a, the major virulence factor of these pathogens, whereas the other antibiotics increase OMV production without the toxin. These two effects might worsen the clinical outcome of infections caused by Shiga toxin-producing E. coli. Our data support the existing recommendations to avoid antibiotics for treatment of these infections.

[1]  A. Mellmann,et al.  Host cell interactions of outer membrane vesicle-associated virulence factors of enterohemorrhagic Escherichia coli O157: Intracellular delivery, trafficking and mechanisms of cell injury , 2017, PLoS pathogens.

[2]  L. Hartling,et al.  Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  A. Charlett,et al.  Disease severity of Shiga toxin-producing E. coli O157 and factors influencing the development of typical haemolytic uraemic syndrome: a retrospective cohort study, 2009–2012 , 2016, BMJ Open.

[4]  Hideo Tanaka,et al.  A role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection. , 2015, International journal of antimicrobial agents.

[5]  Björn Kemper,et al.  Virulence from vesicles: Novel mechanisms of host cell injury by Escherichia coli O104:H4 outbreak strain , 2015, Scientific Reports.

[6]  B. Devreese,et al.  The effect of imipenem and diffusible signaling factors on the secretion of outer membrane vesicles and associated Ax21 proteins in Stenotrophomonas maltophilia , 2015, Front. Microbiol..

[7]  C. Nakamura,et al.  Structural Changes and Differentially Expressed Genes in Pseudomonas aeruginosa Exposed to Meropenem-Ciprofloxacin Combination , 2014, Antimicrobial Agents and Chemotherapy.

[8]  M. Kuehn,et al.  Stress-Induced Outer Membrane Vesicle Production by Pseudomonas aeruginosa , 2013, Journal of bacteriology.

[9]  M. Christner,et al.  Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Ulrich C. Klostermeier,et al.  Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study , 2012, BMJ : British Medical Journal.

[11]  A. Mellmann,et al.  Effects of Antibiotics on Shiga Toxin 2 Production and Bacteriophage Induction by Epidemic Escherichia coli O104:H4 Strain , 2012, Antimicrobial Agents and Chemotherapy.

[12]  B. Arulanandam,et al.  Vesiculation from Pseudomonas aeruginosa under SOS , 2012, TheScientificWorldJournal.

[13]  C. Hedberg,et al.  Antibiotic Treatment of Escherichia coli O157 Infection and the Risk of Hemolytic Uremic Syndrome, Minnesota , 2012, The Pediatric infectious disease journal.

[14]  M. Kuehn,et al.  Contribution of bacterial outer membrane vesicles to innate bacterial defense , 2011, BMC Microbiology.

[15]  Klaus Stark,et al.  Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. , 2011, The New England journal of medicine.

[16]  A. Mellmann,et al.  Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. , 2011, The Lancet. Infectious diseases.

[17]  J. Rothberg,et al.  Prospective Genomic Characterization of the German Enterohemorrhagic Escherichia coli O104:H4 Outbreak by Rapid Next Generation Sequencing Technology , 2011, PloS one.

[18]  P. Tarr,et al.  Acute bloody diarrhea: a medical emergency for patients of all ages. , 2009, Gastroenterology.

[19]  M. Kuehn,et al.  Release of outer membrane vesicles by Gram-negative bacteria is a novel envelope stress response , 2007, Molecular microbiology.

[20]  H. Karch,et al.  Enterohaemorrhagic Escherichia coli in human medicine. , 2005, International journal of medical microbiology : IJMM.

[21]  P. Tarr,et al.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome , 2005, The Lancet.

[22]  G. Nair,et al.  Release of Shiga Toxin by Membrane Vesicles in Shigella dysenteriae Serotype 1 Strains and In Vitro Effects of Antimicrobials on Toxin Production and Release , 2004, Microbiology and immunology.

[23]  E. Seidman,et al.  Pathogenesis of Shiga Toxin-Associated Hemolytic Uremic Syndrome , 2001, Pediatric Research.

[24]  C. Harwood,et al.  Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. , 2000, Emerging infectious diseases.

[25]  Craig S. Wong,et al.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. , 2000, The New England journal of medicine.

[26]  M. Waldor,et al.  Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. , 2000, The Journal of infectious diseases.

[27]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[28]  H. Karch,et al.  Strain-Specific Differences in the Amount of Shiga Toxin Released from Enterohemorrhagic Escherichia coli O157 following Exposure to Subinhibitory Concentrations of Antimicrobial Agents , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[29]  D. Acheson,et al.  Regulation of the Shiga-like toxin II operon in Escherichia coli , 1996, Infection and immunity.